Diabetic Nephropathy — Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
Citation(s)
A Double-Blind, Placebo-Controlled Study on the Effect of Spironolactone, in Patients With Persistent Proteinuria on Long-Term Angiotensin Converting Enzyme Inhibitor Therapy, With or With Out an Angiotensin II Receptor Blocker